Compared with warfarin, dabigatran and rivaroxaban linked to lower risk of adverse renal outcomes
Your search for dabigatran returned 42 results
Effective for dabigatran reversal among patients with uncontrolled bleeding, undergoing urgent surgery
The researchers found that the risk of developing an intraocular hemorrhage was reduced with dabigatran or rivaroxaban at 365 days (hazard ratio, 0.75; 95% confidence interval, 0.58 to 0.97; P=0.03) but not at 90 days (hazard ratio, 0.73; 95% confidence interval, 0.22 to 2.63; P=0.13).
Study of newer medications finds 16 percent receive too much or too little
For patients with atrial fibrillation hospitalized with stroke or transient ischemic attack, use of novel oral anticoagulants (NOACs) has increased over time.
Pradaxa (dabigatran etexilate capsules) 150mg, an oral direct thrombin inhibitor, will be made available by Boehringer Ingelheim on November 3, 2010.
Compared with warfarin, apixaban was correlated with reduced risk of major bleeding and intracranial bleeding (adjusted hazard ratios, 0.66 and 0.4, respectively) and dabigatran was correlated with reduced risk of intracranial bleeding (adjusted hazard ratio, 0.45) among patients with atrial fibrillation.
Investigators found an incremental increase in risks from oral anticoagulants as kidney function decreased, highlighting the need for more research to better understand bleeding risk and net benefit of treatment in the CKD population.
The FDA is alerting healthcare providers and patients of important storage and handling requirements for Pradaxa (dabigatran etexilate mesylate capsules; Boehringer Ingelheim).
Boehringer Ingelheim announced that the FDA has approved Pradaxa (dabigatran etexilate capsules), an oral direct thrombin inhibitor, to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation (AFib).